This Psychedelics Stock Could Grow 300% In One Year

Cantor Fitzgerald initiated coverage of Cybin (NYSE: CYBN), a drug development company in the psychedelics sector.

Analysts gave Cybin an overweight rating and a 12-month price target of $9. Cybin shares were $2.25 at the time of this writing. 

This means that according to the financial firm Cybin stock could give a margin of 300% in just one year.

Cybin debuted on the NYSE earlier this month with a pipeline of novel psychedelic molecules for the treatment of …

Full story available on Benzinga.com

More This Psychedelics Stock Could Grow 300% In One Year